The San Antonio Breast Cancer Symposium (SABCS) 2025 is taking place from December 9–12, 2025, in San Antonio, Texas, serving as one of the world’s premier forums for breast cancer research and clinical innovation. Bringing together oncologists, surgeons, radiologists, scientists, patient advocates, and industry leaders, SABCS 2025 is showcasing cutting-edge advances across the spectrum of breast oncology from translational science and precision therapeutics to diagnostics, survivorship, and global care standards. The meeting is featuring high-impact scientific presentations, educational sessions, late-breaking data, and extensive industry participation. Core content is also being made available online and on-demand, ensuring broad accessibility for the global breast cancer community.
15 Posts Not to Miss from SABC 2025
In this article, we selected 15 key posts you shouldn’t miss, capturing the most impactful insights, research updates, and expert perspectives shared throughout SABC 2025.
“Carboplatin for early stage TNBC. All trials in one slide . It should be given to those who don’t have acess to IO . Those who can receive IO , further question is, if it can reduce anthracycline use . Good discussion SABCS2025 ”
“Don’t miss our SABCS25 Symposium on ADCs moving to earlier lines on Thursday night! Chaired by @BCJoyceO
and featuring Javier Cortes MD , Sybille Loibl and myself.”
“There is nothing – NOTHING – more powerful than the patient voice. I am so grateful to know Abigail Johnston.”
“SABCS San Antonio rapid fire session on TNBC has many great studies. The pooled analysis from 9 NAC trials in GBG/AGO-B showed Ki67 and TILS in residual tumor are highly prognostic for death even in N0 disease. Imp strategy for new Rx selection.”
“Panel discussion on updates from ABC Global Decade Report at SABCS25
MBC needs more across the globe.
Review global report from ABC Global Report
“Educational Session 1: After CDK4/6 Inhibitors-Advancing Treatment for HR+HER2-negative Metastatic Breast Cancer Treatment strategies after CDK4/6 inhibitor progression Mafalda Oliveira at SABCS25 ”
“Excited to take the stage with outstanding colleagues on PER® Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer at SABCS25! Big conversation ahead on how to best use our expanding treatment arsenal.”
“Today on the first day of SABCS 2025 was Special Session 2: Lobular Breast Cancer Updates — gathering researchers, clinicians and patient advocates to share the latest findings on diagnostics, emerging biomarkers, ILC-specific trials, and patient-centered perspectives. The session was chaired by Steffi Oesterreich and Marleen Kok.
This year at SABCS we are all encouraged to see a major signal — 112 talks and posters mentioning “lobular”, reflecting a growing global research focus on lobular breast cancer. The rising visibility at SABCS shows that the community is recognizing its unique biology, long-term behavior, and the need for tailored research and care.
Proud to be part of this movement toward greater awareness and innovation for lobular breast cancer. LobularBreastCancer hashtag#BreastCancerResearch PatientAdvocacy SABCS2025 UPMC Hillman Cancer Center Magee-Womens Research Institute & Foundation Institute for Precision Medicine European Lobular Breast Cancer Consortium (ELBCC)Lobular Breast Cancer UK Lobular Breast Cancer Alliance Inc.”
“Day 1 at SABCS San Antonio is a wrap! A strong start filled with excellent sessions, insightful data, and great conversations with colleagues and friends. Excited for what’s to come at SABCS25!”
“Understanding the impact of lifestyle on cancer risk is critical to reduce the burden of cancer at both an individual and population level. However, study results tend to be mixed on impacts of alcohol and obesity. Most point to correlation if not causation and the space remains confusing for many.
Thrilled to be part of this San Antonio Breast Cancer Symposium Special Session combining lifestyle factors including alcohol consumption and obesity with genetic factors which may provide more insight and guidance on risk of primary breast cancer, breast cancer recurrence, and breast cancer metastasis. Additionally, I’ll be addressing the elephant in the room – how to approach these conversations in clinic.
Join us tomorrow, December 9th at 11amCT to discuss!”
“SABCS25 is off to a great start!”
SABCS25 Day 1 Highlights Community Onc: 1. ALTERNATE: Surgery after NeoAdj ET
2. Role of NeoAdj Carbo in TNBC
3. RJBC1501: Role of Carbo in Adj TNBC
4. CITRINE: Role of Carbo in Adj TNBC
“Dr Erica Mayer with a Harold J. Burstein slide on all our post CDK4/6 inhibitor trials SABCS25”
“Dr Santagata discussing how spatial proteomics can identify treatment biomarkers. My questions: (i) can we prove that these assays add predictive information above “standard” tests; (ii) are these research tools or do they have a future in the clinic?”
“Very important data presented at SABCS25 by our GBG colleagues showing the potential gonadotoxicity of adding immunotherapy (atezolizumab) to chemotherapy in young patients with early triple-negative Breast Cancer.”
More posts about SABCS 2025 on OncoDaily.
Written by Nare Hovhannisyan, MD